# Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

> **NCT00740779** · PHASE2 · COMPLETED · sponsor: **Watson Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

## Interventions

- **DRUG:** Silodosin 8 mg
- **DRUG:** Placebo
- **DRUG:** Silodosin 4 mg

## Key facts

- **NCT ID:** NCT00740779
- **Lead sponsor:** Watson Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2012-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740779, "Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00740779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*